|Articles|September 12, 2005

Market for Surgical and Trauma Wound Care to Surpass $6 Billion by 2009

NEW YORK -- The worldwide market for products to treat surgical and trauma wounds will surpass the $6 billion mark by 2009, according to a study released today from Kalorama Information. Wound closure products, such as sutures and staples, dominate the sector which is currently displaying approximately 7 percent annual growth.

The new study, Wound Care Markets, Volume III: Surgical and Trauma Wounds,

predicts that despite a general slowdown in growth in the next few years, several segments will outperform the sector as a whole. Biological dressings will continue to display double-digit annual growth despite limited use in these types of wounds. Meanwhile, sealants, adhesives, and glues have been catapulting forward at more than 30 percent annually.

The introduction of scores of these new, innovative products has put pressure on marketers and clinicians to standardize product categorizations and indications, adding a new level of complexity to the successful commercialization of wound products.

"There is a decided shift in clinical decision making about dressings, moving toward the drug model -- the specific interactions, indications, side effects, etc. -- rather than categorizing products by components," notes Mary Anne Crandall, RN, the author of the final report. "This new way of thinking about and labeling products is something marketers need to begin positioning themselves for sooner rather than later."

The study examines six broad categories of products and more than 15 subcategories, detailing market size and growth through 2009, presenting competitive market share, and providing a thorough understanding of the environment in which these wound care manufacturers operate.

Source: Kalorama Information, a division of MarketResearch.com


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.